Gelsolin (Gsn) was also decreased in serum at the pre-symptomatic and symptomatic stages, and decreased circulating gelsolin levels have also been reported in GBM patients [69,70] while its tissue expression decreased with grade in astrocytomas [71]. This evidence concerns the gene GSN and glioblastoma.